StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > .16 a share. SZLS isn’t alone in unrealized potential.

<< Previous

Bullboard Posts

Next >>

Comment by gojotv!on Jun 08, 2022 2:50pm

62 Views

Post# 34741225

RE:RE:.16 a share. SZLS isn’t alone in unrealized potential.

That's very cost-effective, compared to current cancer treatment costs. If it works, it will probably be adopted by Health Canada and paid for forthwith.

Nailbiter1 wrote: Administered every 3 weeks for 6 months
Ain't that around $200k for the treatment?
Fine if you are a big billion dollar capitalist
like Mykndrsn but for us wee folk...
Shoot me in da face.